Selank & Semax: Nootropic Peptide Research Overview

Among the peptides to emerge from Russian neurological research, Selank and Semax stand out for their mechanistic originality. Both were developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, both target the central nervous system, and both have accumulated decades of preclinical and clinical data — the majority published in Russian-language journals and thus underappreciated in Western literature. This review summarizes what is known about each compound's mechanism, compares them head-to-head, and outlines research protocols used in the primary literature.

Selank: Mechanism of Action

Tuftsin Analog With Anxiolytic Activity

Selank (TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg). Tuftsin is a tetrapeptide derived from the Fc region of immunoglobulin G and is best known for its immunostimulatory effects on macrophages and neutrophils. Selank retains the tuftsin core but adds three C-terminal residues (Pro-Gly-Pro) that substantially increase its metabolic stability in plasma, extending its effective half-life from approximately 2 minutes (tuftsin) to roughly 20–30 minutes (Selank, Semenova et al., 2010).

Selank's anxiolytic properties are its most studied characteristic. In the primary literature, Selank demonstrates dose-dependent reductions in anxiety in elevated plus maze (EPM) and open-field paradigms in rodents at doses of 100–300 mcg/kg intranasal or SC. Unlike benzodiazepines, Selank's anxiolytic effect does not appear to operate through GABA-A receptor modulation and produces no measurable sedation, tolerance, or withdrawal in chronic-use animal models (Kozlovskaya et al., 2002). This selectivity makes it a valuable research tool for dissecting the anxiolytic pathways that don't depend on GABAergic suppression.

BDNF Upregulation

A consistent finding across multiple Selank studies is upregulation of brain-derived neurotrophic factor (BDNF) in the hippocampus. Selank administration (100 mcg/kg for 5 days) in rats with experimental anxiety produced a 1.6–2.0× increase in BDNF mRNA expression in hippocampal tissue compared to vehicle controls, alongside parallel reductions in corticotropin-releasing factor (CRF) and elevated GABA transporter expression (Semenova et al., 2010). BDNF upregulation is thought to mediate part of Selank's anxiolytic and potential cognitive-enhancing effects by supporting hippocampal neuroplasticity — a mechanism with parallels to the ketamine-like rapid antidepressant hypothesis.

IL-6 and Immune Modulation

Because Selank derives from tuftsin, it retains measurable immunomodulatory activity. Studies using experimental models of systemic infection found that Selank modulates the expression of a panel of interleukins: it appears to suppress excess IL-6 production in pro-inflammatory states while preserving baseline immune function (Filatova et al., 2007). Selank also affects expression of IL-4, IL-10, and interferon-gamma in lymphocytes in vitro. The clinical implication of this dual immune-CNS action is an active area of investigation, particularly in models of depression and anxiety driven by neuroinflammation.

Semax: Mechanism of Action

ACTH(4-7)PGP Analog With Nootropic and Neuroprotective Effects

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide based on the ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro extension. The parent sequence ACTH(4-7) is the active melanocortin receptor-binding core of adrenocorticotropic hormone. Critically, Semax lacks the steroidogenic activity of full ACTH — it does not stimulate cortisol production via the HPA axis — which makes it useful for studying CNS effects of melanocortin receptor activation independently of adrenal consequences. Semax is delivered intranasally in most research and clinical protocols, achieving CNS bioavailability via olfactory epithelium transport at a fraction of the IV dose required for equivalent brain exposure.

BDNF and VEGF Upregulation

Semax's most replicated finding is robust upregulation of BDNF in hippocampal and prefrontal cortical tissue. Rat studies using intranasal Semax at 50–250 mcg/kg show 2–4× BDNF mRNA and protein increases in the hippocampus within 1–3 hours of administration, peaking at 6–12 hours (Dolotov et al., 2006). In ischemia models (MCAO rat), Semax post-administration significantly reduces infarct volume and upregulates VEGF expression in peri-infarct cortex, suggesting the angiogenic and neuroprotective mechanisms may operate in parallel (Agapova et al., 2007). The BDNF upregulation pathway for Semax appears distinct from that of Selank: Semax primarily activates TrkB signaling via BDNF release rather than through direct receptor modulation, and its VEGF arm may be downstream of HIF-1α activation in hypoxic/ischemic tissue.

Cognitive and Attention Effects

Russian clinical trials of Semax in stroke rehabilitation and attention deficit conditions have reported improvements on cognitive battery measures, including working memory tasks and sustained attention. A placebo-controlled study of patients with mild cognitive impairment (n=65) found that intranasal Semax (2,000 mcg/day for 10 days) produced statistically significant improvements on digit span, attention switching, and verbal recall tasks versus placebo (Kaplan et al., 1996, cited in Andreeva et al., 2000). Animal models using Morris water maze and radial arm maze confirm dose-dependent memory acquisition improvements at 50–100 mcg/kg SC or intranasal.

Dopamine and serotonin system modulation may contribute to Semax's focus-enhancing effects. Microdialysis studies in rat prefrontal cortex show Semax increases extracellular dopamine and serotonin at 100 mcg/kg IN, with peak effects at 30–60 minutes post-dose. This monoamine component differentiates Semax from racetams and other nootropic classes and suggests care is warranted in research designs where dopaminergic/serotonergic confounders would invalidate results.

Head-to-Head Mechanism Comparison

Despite their similar nootropic reputations, Selank and Semax have meaningfully different mechanisms and optimal research applications:

• Receptor target: Selank likely acts through opioid/GABAergic modulation and direct BDNF expression; Semax acts via melanocortin receptors (MC4R, MC5R) and downstream BDNF/VEGF release
• Primary effect: Selank is primarily anxiolytic with secondary nootropic effects; Semax is primarily nootropic/neuroprotective with secondary anxiolytic effects
• Stress axis: Selank reduces CRF expression and normalizes the HPA axis; Semax does not activate cortisol production but does influence HPA response acutely via MC2R-independent pathways
• Immune activity: Selank has direct immunomodulatory activity (tuftsin heritage); Semax has minimal direct immune effect but may have indirect anti-inflammatory action via BDNF/VEGF signaling
• BDNF mechanism: Selank upregulates BDNF transcription directly; Semax triggers BDNF release and TrkB receptor activation more acutely
• Delivery route: Both are suitable for intranasal delivery; intranasal is the preferred route in most published Semax research
• Sedation risk: Selank — none reported; Semax — minimal, though dopaminergic stimulation may increase arousal
• Best research use case: Selank for non-GABAergic anxiety models, stress-neuroinflammation links; Semax for cognition, neuroprotection, stroke models, BDNF pathway research

Research Protocols and Dosing

Selank Dosing in Preclinical Research

Published rodent studies use Selank at 100–300 mcg/kg intranasal or subcutaneous. Acute single-dose administration is sufficient to observe EPM anxiolytic effects; BDNF upregulation and immune modulation effects have been studied over 5–14 day chronic protocols. For chronic administration, studies have used once- or twice-daily dosing without evidence of receptor desensitization. Selank is typically reconstituted in sterile saline or PBS and stored at 2–8°C for short-term use or −20°C for long-term storage.

Semax Dosing in Preclinical Research

Rodent intranasal protocols use 50–200 mcg/kg, with cognitive effect studies typically using 100 mcg/kg once daily for 5–10 days. Neuroprotection and ischemia studies use acute post-insult dosing (50–200 mcg/kg IM or IN) with measurement windows at 24h, 72h, and 7 days. Russian clinical trials have used 900–2,000 mcg/day intranasally in divided doses. Because intranasal delivery efficiency varies with administration technique, researchers should standardize volume (5–10 µL/nostril) and head position to minimize inter-animal variability.

Combination Protocols

Several research groups have used Selank and Semax sequentially rather than concurrently — for example, Selank during stress induction phases (to test whether anxiolytic pre-treatment modulates subsequent cognitive challenge) and Semax during cognitive testing phases. Concurrent use has not been extensively studied and represents a gap in the published literature. The interaction between Selank's immune modulation and Semax's VEGF-driven angiogenic activity in CNS tissue would be a productive area for future investigation.

Reconstitution and Storage

• Reconstitute in sterile bacteriostatic water or isotonic saline (0.9% NaCl) for SC/IM use
• For intranasal delivery: reconstitute in sterile saline to achieve 500–1,000 mcg/mL and use a micropipette or nasal applicator
• Store lyophilized peptide at −20°C, away from light and moisture
• After reconstitution: store at 2–8°C, use within 14–21 days; minimize freeze-thaw cycles
• Both peptides are stable in solution for several hours at room temperature but should not be stored unconstituted at RT for extended periods
• Avoid repeated freeze-thaw cycles (>2 cycles will degrade potency)

Research Design Considerations

• Include vehicle controls: both peptides are intranasal candidates — control animals should receive equivalent saline intranasal volume to account for intranasal handling stress
• Measure BDNF and VEGF protein levels (ELISA) in addition to behavioral endpoints when possible — these serve as mechanistic confirmation of compound activity
• Use diazepam or a known anxiolytic as a positive control in Selank EPM studies to establish assay sensitivity
• For Semax cognitive studies, include a no-treatment baseline to distinguish learning curve effects from compound effects across sessions
• Power calculations for cognitive endpoints require larger n than anxiety endpoints (typically n≥10/group for memory tasks vs n≥6–8 for EPM)
• For BDNF mRNA studies, tissue collection timing matters: Selank effects peak at ~3–6h post-dose; Semax BDNF peaks at ~6–12h post-dose — use these windows for tissue harvest

Selank and Semax represent a productive and underexplored area of CNS peptide research, particularly for Western researchers unfamiliar with the Russian literature. The mechanistic differences between them — despite their similar nootropic reputations — make them valuable research tools precisely because they allow the investigator to ask distinct questions about non-GABAergic anxiolysis, BDNF signaling routes, and the relationship between immune modulation and cognitive function.